For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenues | - | 0 | - | 366 |
| Research and development | 8 | 14 | 19 | 814 |
| General and administrative | 858 | 1,534 | 1,828 | 2,209 |
| Loss on mannkind transaction | - | 0 | - | - |
| Total operating expenses | 866 | 1,548 | 1,847 | 3,023 |
| Loss from operations | -866 | -1,548 | -1,847 | -2,657 |
| Interest income | 30 | 41 | - | - |
| Other expense, net | -41 | -43 | -80 | -31 |
| Interest income | - | - | 53 | 101 |
| Fair value adjustment of warrants | - | -1 | -66 | - |
| Total other income (expense), net | -11 | -1 | 39 | 70 |
| Net loss | -877 | -1,549 | -1,808 | -2,587 |
| Net loss per share attributable to common stockholders basic | -0.24 | -0.42 | 0.5 | -0.71 |
| Net loss per share attributable to common stockholders diluted | -0.24 | -0.42 | 0.5 | -0.71 |
| Weighted average common shares outstanding basic | 3,652,285 | 3,652,285 | 3,652,285 | 3,652,285 |
| Weighted average common shares outstanding diluted | 3,652,285 | 3,652,285 | 3,652,285 | 3,652,285 |
Pulmatrix, Inc. (PULM)
Pulmatrix, Inc. (PULM)